Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak.
Jew Win KuanAnselm Ting SuSiow Phing TayIsabel Lim FongSho KubotaLela Su'utMotomi OsatoGoro SashidaPublished in: International journal of hematology (2019)
The BCR-ABL1 fusion gene is the driver mutation of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Its expression level in CML patients is monitored by a real-time quantitative polymerase chain reaction defined by the International Scale (qPCRIS). BCR-ABL1 has also been found in asymptomatic normal individuals using a non-qPCRIS method. In the present study, we examined the prevalence of BCR-ABL1 in a normal population in southern Sarawak by performing qPCRIS for BCR-ABL1 with ABL1 as an internal control on total white blood cells, using an unbiased sampling method. While 146 of 190 (76.8%) or 102 of 190 (53.7%) samples showed sufficient amplification of the ABL1 gene at > 20,000 or > 100,000 copy numbers, respectively, in qPCRIS, one of the 190 samples showed amplification of BCR-ABL1 with positive qPCRIS of 0.0023% and 0.0032% in two independent experiments, the sequence of which was the BCR-ABL1 e13a2 transcript. Thus, we herein demonstrated that the BCR-ABL1 fusion gene is expected to be present in approximately 0.5-1% of normal individuals in southern Sarawak.
Keyphrases
- chronic myeloid leukemia
- copy number
- genome wide
- risk factors
- end stage renal disease
- chronic kidney disease
- gene expression
- induced apoptosis
- genome wide identification
- poor prognosis
- acute lymphoblastic leukemia
- ejection fraction
- high resolution
- oxidative stress
- peritoneal dialysis
- transcription factor
- genome wide analysis